For instance, cetuximab targeting epidermal growth factor receptor (EGFR), bevacizumab against vascular endothelial growth factor receptor (VEGFR), and dabrafenib inhibiting BRAF V600E mutation has become cornerstone of anti-tumor treatments and considerably improve the prognosis of advanced cancer patients [24–26]. The gene discussed is BRAF; the disease is cancer.